BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 29368155)

  • 1. NK/T Cell Lymphoma: Updates in Therapy.
    Suzuki R
    Curr Hematol Malig Rep; 2018 Feb; 13(1):7-12. PubMed ID: 29368155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Features and Current Optimal Management of Natural Killer/T-Cell Lymphoma.
    Makita S; Tobinai K
    Hematol Oncol Clin North Am; 2017 Apr; 31(2):239-253. PubMed ID: 28340876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia.
    Suzuki R
    Int J Hematol; 2010 Dec; 92(5):697-701. PubMed ID: 21116747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type.
    Yamaguchi M; Suzuki R; Oguchi M
    Blood; 2018 Jun; 131(23):2528-2540. PubMed ID: 29602763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis and treatment of extranodal natural killer/T-cell lymphoma.
    Suzuki R
    Semin Hematol; 2014 Jan; 51(1):42-51. PubMed ID: 24468315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extranodal NK/T-cell lymphoma: Updates in biology and management strategies.
    Yamaguchi M; Oguchi M; Suzuki R
    Best Pract Res Clin Haematol; 2018 Sep; 31(3):315-321. PubMed ID: 30213402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Extranodal NK/T-cell lymphoma].
    Suzuki R
    Nihon Rinsho; 2014 Mar; 72(3):524-30. PubMed ID: 24724414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan.
    Yamaguchi M; Suzuki R; Oguchi M; Asano N; Amaki J; Akiba T; Maeda T; Itasaka S; Kubota N; Saito Y; Kobayashi Y; Itami J; Ueda K; Miyazaki K; Ii N; Tomita N; Sekiguchi N; Takizawa J; Saito B; Murayama T; Ando T; Wada H; Hyo R; Ejima Y; Hasegawa M; Katayama N
    J Clin Oncol; 2017 Jan; 35(1):32-39. PubMed ID: 28034070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus-associated natural killer/T-cell lymphomas.
    Asano N; Kato S; Nakamura S
    Best Pract Res Clin Haematol; 2013 Mar; 26(1):15-21. PubMed ID: 23768637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
    Yoon DH; Kim SJ; Jeong SH; Shin DY; Bae SH; Hong J; Park SK; Yhim HY; Yang DH; Lee H; Kang HJ; Lee MH; Eom HS; Kwak JY; Lee JH; Suh C; Kim WS
    Oncotarget; 2016 Dec; 7(51):85584-85591. PubMed ID: 27542213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.
    Wang YQ; Yang Y; Zhuo HY; Zou LQ; Jiang Y; Jiang M
    Med Oncol; 2015 Feb; 32(2):435. PubMed ID: 25572807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extranodal natural killer/T cell lymphoma: we should and we can do more.
    Ying Z; Zhu J
    Chin Clin Oncol; 2015 Mar; 4(1):12. PubMed ID: 25841719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients.
    Wang X; Hu J; Dong M; Ding M; Zhu L; Wu J; Sun Z; Li X; Zhang L; Li L; Wang X; Fu X; Wang G; Chen Q; Zhang M; Zhang X
    Clin Transl Sci; 2021 Jan; 14(1):405-411. PubMed ID: 33045134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
    Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R
    J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and future management of NK/T-cell lymphoma based on clinical trials.
    Yamaguchi M
    Int J Hematol; 2012 Nov; 96(5):562-71. PubMed ID: 23073619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL).
    Lee J; Cho SG; Chung SM; Ryu MR; Kim SH; Jang HS; Choi BO
    Ann Hematol; 2013 Mar; 92(3):333-43. PubMed ID: 23180438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
    Oh D; Ahn YC; Kim SJ; Kim WS; Ko YH
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):677-83. PubMed ID: 26461010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current treatment approaches for NK/T-cell lymphoma.
    Yamaguchi M; Miyazaki K
    J Clin Exp Hematop; 2017 Dec; 57(3):98-108. PubMed ID: 28679966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of NK/T-cell lymphoma: current situations and prospectives].
    Yamaguchi M
    Rinsho Ketsueki; 2018; 59(5):588-593. PubMed ID: 29877250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NK-Cell Lymphomas.
    Chihara D; Oki Y
    Cancer Treat Res; 2019; 176():163-184. PubMed ID: 30596218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.